BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present AI-Enabled Drug Discovery Keynote at 22nd Drug Discovery Strategic Summit

Oncotelic Therapeutics (OTCQB: OTLC) announced that Chief Business Officer Saran Saund will deliver the opening keynote on the second day of the 22nd Drug Discovery Strategic Summit on Oct. 22, 2026, at 9 a.m. Pacific Time in Millbrae, California. The presentation will explore partition and aggregation as an organizing principle for AI-enabled drug discovery, emphasizing how complex research questions can be divided into focused investigations and findings combined to develop testable hypotheses. Saund will discuss the company’s proprietary PDAOAI platform, which indexes approximately 29 million PubMed abstracts, along with its international intellectual property strategy, planned expansion into genetic discovery and Fastbot/Membot technology designed to make AI-powered research accessible to individual investigators.

To view the full press release, visit https://ibn.fm/O1lLk

About Oncotelic

Oncotelic Therapeutics, Inc. develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications. The Company also develops the PDAOAI platform to support its work in drug discovery and development.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN